Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
US Department of Justice
Cipla
US Army
Dow
Fuji
Citi
Merck
Federal Trade Commission

Generated: December 19, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR INTRALIPID 20%

« Back to Dashboard

Clinical Trials for Intralipid 20%

Trial ID Title Status Sponsor Phase Summary
NCT00005889 Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion Unknown status Baylor College of Medicine N/A RATIONALE: Very low birth weight infants have problems maintaining normal blood sugar levels. Gluconeogenesis is the production of sugar from amino acids and fats. The best combination of amino acids, fat, and sugar to help very low birth weigh infants maintain normal blood sugar levels is not yet known. PURPOSE: Clinical trial to study how very low birth weight infants break down amino acids, fat, and sugar given by intravenous infusion, and the effect of different combinations of nutrients on the infants' ability to maintain normal blood sugar levels.
NCT00005889 Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion Unknown status National Center for Research Resources (NCRR) N/A RATIONALE: Very low birth weight infants have problems maintaining normal blood sugar levels. Gluconeogenesis is the production of sugar from amino acids and fats. The best combination of amino acids, fat, and sugar to help very low birth weigh infants maintain normal blood sugar levels is not yet known. PURPOSE: Clinical trial to study how very low birth weight infants break down amino acids, fat, and sugar given by intravenous infusion, and the effect of different combinations of nutrients on the infants' ability to maintain normal blood sugar levels.
NCT00048646 Progesterone Treatment of Blunt Traumatic Brain Injury Completed National Institute of Neurological Disorders and Stroke (NINDS) Phase 1/Phase 2 The purpose of this study is to determine if progesterone treatment safely reduces brain swelling and damage after injury.
NCT00048646 Progesterone Treatment of Blunt Traumatic Brain Injury Completed David Wright Phase 1/Phase 2 The purpose of this study is to determine if progesterone treatment safely reduces brain swelling and damage after injury.
NCT00074477 Safety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 2 The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate injection compared to placebo in the treatment of the symptoms of schizophrenia in adults. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings.
NCT00088647 Study Evaluating MST-997 in Advanced Malignant Solid Tumors Terminated Wyeth is now a wholly owned subsidiary of Pfizer Phase 1 The primary objective of this clinical research study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of intravenous (IV) MST-997 formulated in Intralipid 20% administered on a weekly schedule to subjects with advanced malignant solid tumors.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Intralipid 20%

Condition Name

Condition Name for Intralipid 20%
Intervention Trials
Parenteral Nutrition 6
Cholestasis 5
Insulin Resistance 4
Obesity 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Intralipid 20%
Intervention Trials
Insulin Resistance 10
Cholestasis 8
Liver Diseases 6
Infertility 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Intralipid 20%

Trials by Country

Trials by Country for Intralipid 20%
Location Trials
United States 53
Canada 14
Egypt 6
France 4
Netherlands 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Intralipid 20%
Location Trials
Texas 5
Georgia 5
Massachusetts 4
Illinois 4
Tennessee 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Intralipid 20%

Clinical Trial Phase

Clinical Trial Phase for Intralipid 20%
Clinical Trial Phase Trials
Phase 4 21
Phase 3 10
Phase 2/Phase 3 6
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Intralipid 20%
Clinical Trial Phase Trials
Completed 27
Recruiting 16
Not yet recruiting 7
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Intralipid 20%

Sponsor Name

Sponsor Name for Intralipid 20%
Sponsor Trials
Fresenius Kabi 5
Emory University 5
University Health Network, Toronto 4
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Intralipid 20%
Sponsor Trials
Other 74
Industry 19
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Dow
Moodys
Fuji
Teva
Baxter
Healthtrust
QuintilesIMS
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.